What is core patent covering Etonogestrel?

Introduction to Etonogestrel 
Etonogestrel is a synthetic progestin derived from 19‐norprogesterone that plays a central role in modern hormonal contraception. It is formulated to provide sustained, controlled release of active principles and is frequently employed in long-acting reversible contraceptive devices. As both an active pharmaceutical ingredient and a component of sophisticated drug delivery systems, etonogestrel’s development has been underpinned by extensive pharmaceutical and chemical research. Overall, its evolution represents a marriage of precise chemical engineering and advanced polymer science to ensure both efficacy and safety in clinical applications.

Chemical and Pharmacological Overview 
Chemically, etonogestrel is characterized by its lipophilic nature and structural modifications that confer high potency at low concentrations. Its molecular design allows for rapid absorption following implantation while ensuring a sustained release profile over an extended period. The chemical formulation of etonogestrel is often integrated into a polymeric matrix—typically a blend of a progestin hormone with polymers such as ethylene vinyl acetate (EVA), sometimes referred to by formulations like EVA-28—to achieve a controlled release environment. Variations in the polymer composition, including precise weight ratios (commonly around 60 wt % etonogestrel combined with 40 wt % EVA-28), are critical design parameters that affect the device’s pharmacokinetic profile and hence its clinical performance. Moreover, additional excipients such as magnesium stearate and radiopaque materials like barium sulfate are incorporated to improve implant visibility and mechanical integrity while ensuring consistent drug release over time. The molecular stability, solubility, and release kinetics of etonogestrel reflect a careful balance between chemical properties of the hormone and the selected polymer media, providing an excellent example of formulation science in practice.

Clinical Applications and Uses 
Clinically, etonogestrel is best known for its use in reversible contraception. It is deployed in subdermal implants (commonly referenced via names like Implanon® or Nexplanon®) that are inserted near the inner side of the upper arm. These implants are designed to deliver effective contraceptive coverage for up to three years, preventing ovulation and inducing changes in the cervical mucus that hinder sperm migration. Owing to its progestational qualities, etonogestrel is not only used to inhibit ovulation but also exerts beneficial effects on the endometrium, making implantation less likely. The implant’s design, including its radiopaque properties through additives like barium sulfate, ensures that clinicians can readily locate the device via X-ray imaging, which is crucial in cases where explantation is necessary for safety reasons. Beyond contraception, research indicates that etonogestrel’s modulation of hormonal pathways has spurred investigation into its potential off-label uses, including in models of respiratory stimulation where it appears to enhance CO2 chemoreflexes in hypoventilation disorders. The versatility of etonogestrel in these areas not only underscores its clinical importance but also emphasizes the need for secure intellectual property protection to incentivize further research and development.

Patent Landscape of Etonogestrel 
The patent landscape surrounding etonogestrel is multifaceted, reflecting the extensive investment in formulation science, controlled drug delivery, and the associated manufacturing processes. Over the years, numerous patents have been filed relating to different aspects of etonogestrel and its delivery systems. These cover a wide range of innovations, from the synthesis of new progestogen esters to the evolution of radiopaque contraceptive implants. Given its central role in hormonal contraception, etonogestrel is not only protected through process claims that safeguard its manufacture but also through composition‐of‐matter claims that specifically delineate its polymer-based matrix formulations.

Overview of Patents Related to Etonogestrel 
There exists a cluster of patents covering various intellectual property aspects of etonogestrel. Many patents focus on the chemical modification of the active ingredient, including the development of novel etonogestrel esters that provide improved pharmacokinetic features or alternative routes of administration. Additionally, significant attention has been given to the medical device aspects, particularly the controlled-release subdermal implant configuration. Patents covering the composition of these implants, as exemplified by the incorporation of specific percentages of etonogestrel with biocompatible polymers like EVA, are a critical subset of these filings. Furthermore, documents such as the patient labeling provided for Nexplanon® detail the clinical uniformity and sustained action provided by the device, aspects that are underpinned by proprietary core formulations. The patent documents and regulatory submissions evaluated for these devices not only disclose the bioavailability and sustained concentration levels of etonogestrel in the bloodstream but also iteratively improve on safety profiles by eliminating estrogenic components and incorporating radiopaque additives for monitoring purposes. In sum, while the patent portfolio for etonogestrel is broad, a subset of these documents clearly stands out as foundational to the overall technology—these are known as “core patents.”

Identification of Core Patent 
Among the diverse filings, one patent in particular has been recognized as a core patent covering the essential technology of controlled-release etonogestrel implants. Drawing on detailed descriptions from patent documents, the core patent can be identified as US Patent No. US 8,722,037 B2. This patent is central in that it specifically discloses the composition and methodology for manufacturing the core of the etonogestrel implant. The core patent elucidates the precise formulation—commonly a mixture containing around 60 wt % etonogestrel combined with 40 wt % of an EVA copolymer (notably EVA-28)—which has been found critical for the sustained and steady release of the hormone into systemic circulation over a prolonged period.

The core patent not only outlines the optimal ratios and choice of materials but also includes claims regarding the incorporation of additional components such as radiopaque substances. These additives ensure that the implant remains detectable on X-ray, a feature vital for proper monitoring and potential retrieval of the device. Thus, by protecting the fundamental composition and release kinetics of the etonogestrel implant, the core patent serves as the cornerstone of subsequent innovations and improvements in the field. Its claims extend to the methods of manufacturing the implant, ensuring that both the product and the process remain under robust intellectual property protection.

Analysis of Core Patent 
In-depth analysis of the identified core patent (US 8,722,037 B2) reveals the multifaceted nature of its claims, protection scope, and strategic positioning within the competitive landscape. This patent plays an instrumental role in defining the technical criteria for modern etonogestrel implants, thereby ensuring that innovations in controlled-release formulations continue to be both effective and safe.

Key Claims and Scope 
The key claims of the core patent revolve around its unique matrix composition, which consists essentially of etonogestrel embedded within a polymeric framework. One of the central claims of the patent is the specific ratio where etonogestrel constitutes approximately 60% of the core by weight, complemented by about 40% of an ethylene vinyl acetate copolymer such as EVA-28. This specific formulation is crucial because it directly influences the rate at which etonogestrel is released, thereby ensuring steady serum levels, sustained contraceptive efficacy, and overall biological stability.

Beyond the ratio of active ingredient to polymer, claims also encompass the inclusion of additional excipients that fulfil critical secondary functions. For example, the use of barium sulfate is disclosed to impart radiopacity to the implant, which is essential for its visualization via radiographic imaging and the management of implant migration or removal complications. Other claims detailed in the patent encompass the method of preparation, where uniform mixing of etonogestrel with the polymer and subsequent forming processes create an implant that exhibits both mechanical integrity and controlled drug release, a factor paramount for long-term contraceptive action.

The breadth of the claims in the core patent covers not just the end product but also the manufacturing processes and quality control measures necessary to attain the exact chemical and physical properties that have been proven to work in vivo. Thus, the scope of the patent extends to any formulation that replicates or approximates the described weight percentages, structural configurations, or manufacturing processes aimed at achieving similar release kinetics. By doing so, the patent effectively creates a significant barrier to entry against competitors seeking to produce similar long-acting reversible contraceptive implants without licensing the technology.

From a technical perspective, the claims articulate both the design and functionality of the implant. On the design front, detailed discussions of the polymer’s thermal properties, its compatibility with etonogestrel, and its resistance to degradation over time are provided. Functionality claims, on the other hand, focus on the kinetics of drug release, which is tailored to maintain adequate hormone levels for up to three years, thereby ensuring both patient compliance and clinical efficacy. Such comprehensive coverage makes the core patent a linchpin in any intellectual property strategy for etonogestrel-based contraceptive devices.

Patent Legal Status and Expiry 
US Patent No. US 8,722,037 B2 is a granted patent that represents one of the most robust and strategically important protections in the etonogestrel portfolio. As a granted patent (B2 status), it has undergone rigorous examination and has been validated as novel, non-obvious, and useful. Given the standard duration of patent protection—a term of up to 20 years from the filing date—the core patent ensures market exclusivity for a significant period. Although the exact filing and grant dates are not provided in the summary materials, typical lifecycle management indicates that even a core patent in this technology area remains active for an extended timeframe, subject to maintenance fees and applicable extensions.

Moreover, in the pharmaceutical and medical device domains, the effective lifespan of a patent may be further extended through regulatory exclusivities or patent term adjustments, particularly when the product undergoes a rigorous approval process. Hence, while the standard patent term offers initial exclusivity, companies may benefit from additional market protection measures that delay generic competition further than the nominal expiration date. Such extensions are critical given the lengthy development cycles associated with drug-device combination products.

It is also important to note that while the patent itself provides broad protection over the core formulation, the legal status of the patent may be subject to litigation, challenges, or reexaminations, as is common in competitive sectors. However, as of the available data, there is no public record indicating that US 8,722,037 B2 has been invalidated or significantly narrowed by subsequent legal challenges. In addition, the associated patent portfolio of etonogestrel-related devices is often maintained in synchrony to create a “protection umbrella,” ensuring that even if one particular claim faces a challenge, the collective intellectual property remains robust.

From a legal standpoint, this core patent has been instrumental in ensuring that the controlled-release technologies of etonogestrel implants are not easily replicated by competitors. Its legal standing, bolstered by detailed claims on the polymer matrix and its manufacturing methods, makes it an essential asset for any company operating in the contraceptive market.

Implications of the Core Patent 
The core patent covering etonogestrel not only secures a competitive advantage for the patent holder but also shapes the broader market dynamics, influencing competition, innovation, and research trajectories in the field of hormonal contraception.

Impact on Market and Competition 
The market for long-acting reversible contraceptives (LARCs) has grown substantially over the past decades, and the introduction of etonogestrel implants has been one of the key drivers behind this trend. The core patent described herein has had a profound impact on market exclusivity, ensuring that manufacturers, such as Organon and its subsidiaries, enjoy a period of limited competition during which they can recoup research and development investments.

The exclusivity granted by the core patent means that competitors are precluded from offering similar products that rely on the patented polymer composition and controlled release technology. This protection has allowed companies not only to dominate the market by offering a well-established product like Nexplanon® but also to invest in further enhancements and additional clinical indications. The barrier to entry established by the core patent serves as an important strategic tool, limiting the rapid proliferation of generic alternatives until the patent or regulatory exclusivities expire.

On a competitive level, the core patent forms the basis upon which the overall portfolio of etonogestrel-based devices is built. It has influenced the strategies of other players in the market, prompting them to either enter into licensing agreements, pursue alternative formulations, or focus on developing next-generation technologies that may circumvent the existing patent claims. The competitive dynamics are further nuanced by the fact that the patent covers not just the composition itself but also the manufacturing process and quality attributes, making it difficult for competitors to replicate the clinical performance and safety profile without addressing the same technological hurdles.

This patent also has broader economic implications. By ensuring a period of market exclusivity, the core patent indirectly underpins pricing strategies, supply chain decisions, and strategic planning for commercialization. As a result, companies holding such patents can achieve a substantial return on investment, thereby incentivizing further innovation in contraceptive technologies. The ripple effect of such market protection mechanisms is felt through the development of ancillary products, improvements in patient management protocols, and even stimulation of research into new progestin derivatives or combination therapies.

Future Developments and Research Opportunities 
While the current core patent provides robust protection over the existing etonogestrel implant architecture, its existence also sets the stage for numerous future developments and research opportunities. On the innovation front, one clear avenue of exploration is the development of new polymers and excipient systems that could further optimize the release kinetics of etonogestrel. Researchers are actively investigating alternative polymer matrices that might offer even better control over drug release or improved biocompatibility, which could extend the effective lifespan of the implant or reduce side effects.

Concurrently, there is significant interest in the formulation of combination devices that incorporate additional therapeutic agents—such as estrogen-receptor modulators or other synergistic hormones—to create multifunctional implants that address broader therapeutic needs beyond contraception alone. Innovations in device design, such as incorporating micro- or nano-engineered release channels or layered composite materials, are being examined to enhance precision in drug delivery while maintaining the safety profile.

From a patent strategy perspective, as the core patent approaches its expiry or faces potential challenges, companies may invest in follow-on patents that address incremental improvements or novel manufacturing processes. Such strategic patents may not only help extend market exclusivity indirectly but also encourage the overall progression of technology. The combination of a strong initial patent with a sustained pipeline of follow-on innovations can create a formidable intellectual property portfolio that spans generations of product evolution.

Another promising research opportunity lies in the area of personalized medicine. As new diagnostic techniques and patient stratification methods emerge, there is potential to tailor the release profiles of etonogestrel implants based on patient-specific factors. For example, the optimization of release kinetics to match individual metabolic rates, reproductive health needs, or even integration with digital health monitoring devices could be foreseen as the next frontier in contraceptive technology. Such research might eventually lead to devices that not only provide contraception but also actively monitor and manage other aspects of hormonal health, further expanding the utility of the core technology.

Lastly, the global regulatory environment is evolving rapidly. With increased emphasis on both safety and accessibility, there is ongoing discussion on how patents like the core etonogestrel patent might influence pricing, access in low-resource settings, and the broader public health landscape. Future developments might include voluntary patent pools or licensing models that ensure broader access while still maintaining incentives for innovation. The interplay between intellectual property rights and public health policies remains a critical area of focus, presenting both challenges and opportunities for stakeholders in the field.

Conclusion 
In summary, the core patent covering etonogestrel, particularly exemplified by US Patent No. US 8,722,037 B2, represents a cornerstone in the development of long-acting reversible contraceptive implants. It encapsulates the innovative controlled-release technology that integrates approximately 60 wt % etonogestrel with 40 wt % EVA polymer, along with ancillary components—such as radiopaque additives—to ensure both clinical efficacy and safety. The detailed claims within this patent not only protect the specific composition and manufacturing process but also set a high benchmark that has influenced subsequent innovations in the sector.

From a chemical and pharmacological standpoint, etonogestrel is a potent synthetic progestin that, through careful formulation in a polymer matrix, achieves a sustained release profile essential for effective contraception. Clinically, it has revolutionized contraceptive practice by providing reliable, long-term pregnancy prevention, with additional emerging applications in non-contraceptive therapeutic areas.

The patent landscape reflects a broad spectrum of intellectual property, yet the core patent stands out due to its comprehensive coverage of the formulation’s critical aspects. It has maintained strong market exclusivity by addressing both the composition and the methodology of manufacture, thereby forming a formidable barrier against competitors. Legally, its status as a granted patent underpins not only current market strategies but also future research directions. Market implications include sustained competitive advantage and pricing power, while emerging research opportunities span the development of advanced polymer systems, combination therapies, and personalized implant technologies.

In essence, the core patent on etonogestrel is a prime example of how meticulous chemical formulation paired with sophisticated intellectual property strategies can drive substantial innovations in medical devices. This patent has safeguarded a critical technology for years, reinforcing the product’s market position, stimulating further scientific research, and ultimately contributing to improved healthcare outcomes through advanced contraceptive technologies.

Discover Eureka LS: AI Agents Built for Biopharma Efficiency

Stop wasting time on biopharma busywork. Meet Eureka LS - your AI agent squad for drug discovery.

▶ See how 50+ research teams saved 300+ hours/month

From reducing screening time to simplifying Markush drafting, our AI Agents are ready to deliver immediate value. Explore Eureka LS today and unlock powerful capabilities that help you innovate with confidence.